This study reports that subcutaneous testosterone pellets in peri- and postmenopausal women provided sustained hormone release and potential benefits for sexual function, but raised concerns about safety, variability, and dosing inconsistencies.
6 citations
,
November 2010 in “International Journal of Andrology” In a clinical trial, this study found that a modified slow-release oral testosterone formulation improved pharmacokinetics, delaying serum testosterone peaks and reducing serum DHT compared to immediate-release formulations, especially when combined with finasteride.
10 citations
,
October 2010 in “International Journal of Andrology” In this study, co-administration of finasteride with oral testosterone undecanoate in young men with induced hypogonadism had no significant effect on serum testosterone or dihydrotestosterone levels, likely due to TU's unique absorption route.
This narrative review highlights the critical role of intracrine hormone production in peripheral tissues, suggesting that continuous-release subcutaneous testosterone pellet therapy may offer a more effective symptom-driven approach for aging populations, though large-scale randomized controlled trials are needed for confirmation.
81 citations
,
May 2007 in “Fertility and Sterility” This review discusses the safety of testosterone therapy for postmenopausal women and concludes that, aside from hirsutism and acne, it appears safe at physiological doses for several years, though more long-term studies are needed.